Public Release: 

JCI early table of contents for Sept. 3, 2013

JCI Journals

Enhanced luminal breast tumor response to antiestrogen therapy

Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment decisions. In this issue of the Journal of Clinical Investigation, Rebecca Cook and colleagues at Vanderbilt University, found that expression of an oncogene, ERBB3, was enhanced in luminal breast cancers compared to other breast cancer subtypes. Addition of the ERBB3 protein to cultured luminal breast cancer cells increased the growth of the cells; however, depletion of this protein with an antibody promoted cancer cell death, and decreased tumor growth in vitro. The authors also demonstrated that ERBB3 was upregulated in luminal tumor samples and in cancer cell cultures that were treated with the cancer drug fulvestrant. Furthermore, the authors found that fulvestrant treatment in combination with anti-ERBB3 decreased both tumor cell survival and growth. These data suggests that ERBB3 could be a target for treatment of fulvestrant resistant breast cancers.

TITLE: ErbB3 downregulation enhances luminal breast tumor response to antiestrogens

Vanderbilt University, Nashville, TN, USA
Phone: (615) 936-3813; E-mail:

View this article at:

Peritoneal dialysis as an intervention for stroke patients

Ischemic stroke is characterized by an interruption of the blood supply to the brain, which can lead to brain damage and even death. Excess amounts of the excitatory neurotransmitter glutamate are released during stroke events and further exacerbate brain cell death. Currently, there are no effective strategies for combatting the effects ischemic stroke. In this issue of the Journal of Clinical Investigation, José Sánchez-Prieto and colleagues at the Universidad Complutense demonstrate that peritoneal dialysis is an effective treatment for reducing glutamate levels in the blood following a stroke event. In a rat model of ischemic stroke, peritoneal dialysis reduced tissue damage in the brain. Furthermore, the authors found that peritoneal dialysis was able to reduce blood glutamate levels in humans undergoing dialysis for chronic kidney disease, Together, these data suggest that peritoneal dialysis immediately following ischemic stroke may help preserve brain tissue and function.

TITLE: Amelioration of ischemic brain damage by peritoneal dialysis

AUTHOR CONTACT: Jose Sanchez-Prieto
Universidad Complutense, Madrid, , ESP
Phone: 34 91 3943891; Fax: 34 91 3943909; E-mail:

View this article at:


TITLE: Epithelial stem cell mutations that promote squamous cell carcinoma metastasis

University of Colorado Denver, Aurora, CO, USA
Phone: 303-724-3001; E-mail:

View this article at:

TITLE: Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling

Vanderbilt University, Nashville, TN, USA
Phone: 615-936-3099; Fax: 615-936-2029; E-mail:

View this article at:

TITLE: Kruppel-like factor 15 is critical for vascular inflammation

Case Western Reserve University, Cleveland, OH, USA
Phone: 216-368-3607; E-mail:

View this article at:

TITLE: PP2A-Activating Drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

AUTHOR CONTACT: Danilo Perrotti
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Phone: 614-292-3567; Fax: 614-688-4181; E-mail:

View this article at:

TITLE: Accelerated neurodegeneration through chaperone-mediated oligomerization of tau

University of South Florida, Tampa, FL, USA
Phone: 813-396-0639; E-mail:

View this article at:

TITLE: Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses

AUTHOR CONTACT: James E. Crowe, Jr.
Vanderbilt University Medical Center, Nashville, TN, USA
Phone: 615-343-8064; Fax: 615-343-4456; E-mail:

View this article at:

TITLE: Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression

AUTHOR CONTACT: Christian Kurts
Institute of Molecular Medicine and Experimental Immunology, Bonn, UNK, DEU
Phone: 49-228-287-1031; Fax: 49-228-287-1052; E-mail:

View this article at:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.